| pubmed-article:19893201 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19893201 | lifeskim:mentions | umls-concept:C0026769 | lld:lifeskim |
| pubmed-article:19893201 | lifeskim:mentions | umls-concept:C0289884 | lld:lifeskim |
| pubmed-article:19893201 | lifeskim:mentions | umls-concept:C1513400 | lld:lifeskim |
| pubmed-article:19893201 | lifeskim:mentions | umls-concept:C1518681 | lld:lifeskim |
| pubmed-article:19893201 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:19893201 | pubmed:dateCreated | 2009-11-6 | lld:pubmed |
| pubmed-article:19893201 | pubmed:abstractText | Glatiramer acetate (GA, Copaxone) has beneficial effects on the clinical course of relapsing-remitting multiple sclerosis (RRMS). However, the exact molecular mechanisms of GA effects are only partially understood. | lld:pubmed |
| pubmed-article:19893201 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19893201 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19893201 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19893201 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19893201 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19893201 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19893201 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19893201 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19893201 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19893201 | pubmed:issn | 1875-8630 | lld:pubmed |
| pubmed-article:19893201 | pubmed:author | pubmed-author:AchironAnatA | lld:pubmed |
| pubmed-article:19893201 | pubmed:author | pubmed-author:GurevichMicha... | lld:pubmed |
| pubmed-article:19893201 | pubmed:author | pubmed-author:FeldmanAnnaA | lld:pubmed |
| pubmed-article:19893201 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19893201 | pubmed:volume | 27 | lld:pubmed |
| pubmed-article:19893201 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19893201 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19893201 | pubmed:pagination | 63-73 | lld:pubmed |
| pubmed-article:19893201 | pubmed:meshHeading | pubmed-meshheading:19893201... | lld:pubmed |
| pubmed-article:19893201 | pubmed:meshHeading | pubmed-meshheading:19893201... | lld:pubmed |
| pubmed-article:19893201 | pubmed:meshHeading | pubmed-meshheading:19893201... | lld:pubmed |
| pubmed-article:19893201 | pubmed:meshHeading | pubmed-meshheading:19893201... | lld:pubmed |
| pubmed-article:19893201 | pubmed:meshHeading | pubmed-meshheading:19893201... | lld:pubmed |
| pubmed-article:19893201 | pubmed:meshHeading | pubmed-meshheading:19893201... | lld:pubmed |
| pubmed-article:19893201 | pubmed:meshHeading | pubmed-meshheading:19893201... | lld:pubmed |
| pubmed-article:19893201 | pubmed:meshHeading | pubmed-meshheading:19893201... | lld:pubmed |
| pubmed-article:19893201 | pubmed:meshHeading | pubmed-meshheading:19893201... | lld:pubmed |
| pubmed-article:19893201 | pubmed:meshHeading | pubmed-meshheading:19893201... | lld:pubmed |
| pubmed-article:19893201 | pubmed:meshHeading | pubmed-meshheading:19893201... | lld:pubmed |
| pubmed-article:19893201 | pubmed:meshHeading | pubmed-meshheading:19893201... | lld:pubmed |
| pubmed-article:19893201 | pubmed:meshHeading | pubmed-meshheading:19893201... | lld:pubmed |
| pubmed-article:19893201 | pubmed:meshHeading | pubmed-meshheading:19893201... | lld:pubmed |
| pubmed-article:19893201 | pubmed:meshHeading | pubmed-meshheading:19893201... | lld:pubmed |
| pubmed-article:19893201 | pubmed:meshHeading | pubmed-meshheading:19893201... | lld:pubmed |
| pubmed-article:19893201 | pubmed:meshHeading | pubmed-meshheading:19893201... | lld:pubmed |
| pubmed-article:19893201 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19893201 | pubmed:articleTitle | Molecular profiling of glatiramer acetate early treatment effects in multiple sclerosis. | lld:pubmed |
| pubmed-article:19893201 | pubmed:affiliation | Multiple Sclerosis Center, Sheba Medical Center, Tel-Hashomer, Israel. achiron@post.tau | lld:pubmed |
| pubmed-article:19893201 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19893201 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
